Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Recommendations for the radiological diagnosis and follow-up of neuropathological abnormalities associated with tuberous sclerosis complex.

Rovira À, Ruiz-Falcó ML, García-Esparza E, López-Laso E, Macaya A, Málaga I, Vázquez E, Vicente J.

J Neurooncol. 2014 Jun;118(2):205-23. doi: 10.1007/s11060-014-1429-y. Epub 2014 Apr 27.

PMID:
24771286
2.

Unique findings of subependymal giant cell astrocytoma within cortical tubers in patients with tuberous sclerosis complex: a histopathological evaluation.

Katz JS, Frankel H, Ma T, Zagzag D, Liechty B, Zeev BB, Tzadok M, Devinsky O, Weiner HL, Roth J.

Childs Nerv Syst. 2017 Apr;33(4):601-607. doi: 10.1007/s00381-017-3335-z. Epub 2017 Jan 10.

PMID:
28074282
3.

Subependymal giant cell astrocytoma: diagnosis, screening, and treatment. Recommendations from the International Tuberous Sclerosis Complex Consensus Conference 2012.

Roth J, Roach ES, Bartels U, Jóźwiak S, Koenig MK, Weiner HL, Franz DN, Wang HZ.

Pediatr Neurol. 2013 Dec;49(6):439-44. doi: 10.1016/j.pediatrneurol.2013.08.017. Epub 2013 Oct 15.

4.

Regression of subependymal giant cell astrocytomas with RAD001 (Everolimus) in tuberous sclerosis complex.

Yalon M, Ben-Sira L, Constantini S, Toren A.

Childs Nerv Syst. 2011 Jan;27(1):179-81. doi: 10.1007/s00381-010-1222-y. Epub 2010 Aug 12.

PMID:
20703486
5.

Brain lesions in tuberous sclerosis complex. Review.

Grajkowska W, Kotulska K, Jurkiewicz E, Matyja E.

Folia Neuropathol. 2010;48(3):139-49. Review.

6.

Genotype/phenotype in tuberous sclerosis complex: associations with clinical and radiologic manifestations.

Kothare SV, Singh K, Hochman T, Chalifoux JR, Staley BA, Weiner HL, Menzer K, Devinsky O.

Epilepsia. 2014 Jul;55(7):1020-4. doi: 10.1111/epi.12627. Epub 2014 Apr 22.

8.

Management of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC): Clinical recommendations.

Jóźwiak S, Nabbout R, Curatolo P; participants of the TSC Consensus Meeting for SEGA and Epilepsy Management.

Eur J Paediatr Neurol. 2013 Jul;17(4):348-52. doi: 10.1016/j.ejpn.2012.12.008. Epub 2013 Feb 5.

PMID:
23391693
9.

Successful everolimus therapy for SEGA in pediatric patients with tuberous sclerosis complex.

Cappellano AM, Senerchia AA, Adolfo F, Paiva PM, Pinho R, Covic A, Cavalheiro S, Saba N.

Childs Nerv Syst. 2013 Dec;29(12):2301-5. doi: 10.1007/s00381-013-2170-0. Epub 2013 Jun 7.

PMID:
23743818
10.

mTOR Inhibitors in Tuberous Sclerosis Complex.

Curatolo P, Moavero R.

Curr Neuropharmacol. 2012 Dec;10(4):404-15. doi: 10.2174/157015912804143595.

11.

Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.

Kotulska K, Chmielewski D, Borkowska J, Jurkiewicz E, Kuczyński D, Kmieć T, Łojszczyk B, Dunin-Wąsowicz D, Jóźwiak S.

Eur J Paediatr Neurol. 2013 Sep;17(5):479-85. doi: 10.1016/j.ejpn.2013.03.002. Epub 2013 Apr 6.

PMID:
23567018
12.

Everolimus tablets for patients with subependymal giant cell astrocytoma.

Turner SG, Peters KB, Vredenburgh JJ, Desjardins A, Friedman HS, Reardon DA.

Expert Opin Pharmacother. 2011 Oct;12(14):2265-9. doi: 10.1517/14656566.2011.601742. Epub 2011 Aug 1. Review.

13.

Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation.

Chan JA, Zhang H, Roberts PS, Jozwiak S, Wieslawa G, Lewin-Kowalik J, Kotulska K, Kwiatkowski DJ.

J Neuropathol Exp Neurol. 2004 Dec;63(12):1236-42.

PMID:
15624760
14.

Current Use of mTOR Inhibitors for the Treatment of Subependymal Giant Cell Astrocytomas and Epilepsy in Patients with TSC.

Jancic J, Duric V, Ivancevic N, Nikolic B, van den Anker JN, Samardzic J.

Curr Med Chem. 2016;23(37):4260-4269. Review.

PMID:
27739368
15.

Management of subependymal giant cell tumors in tuberous sclerosis complex: the neurosurgeon's perspective.

Berhouma M.

World J Pediatr. 2010 May;6(2):103-10. doi: 10.1007/s12519-010-0025-2. Epub 2010 May 21. Review.

PMID:
20490765
16.

A management strategy for intraventricular subependymal giant cell astrocytomas in tuberous sclerosis complex.

Harter DH, Bassani L, Rodgers SD, Roth J, Devinsky O, Carlson C, Wisoff JH, Weiner HL.

J Neurosurg Pediatr. 2014 Jan;13(1):21-8. doi: 10.3171/2013.9.PEDS13193. Epub 2013 Nov 1.

PMID:
24180681
17.

Rapamycin and rapalogs for tuberous sclerosis complex.

Sasongko TH, Ismail NF, Zabidi-Hussin Z.

Cochrane Database Syst Rev. 2016 Jul 13;7:CD011272. doi: 10.1002/14651858.CD011272.pub2. Review.

PMID:
27409709
18.

Presurgical Administration of mTOR Inhibitors in Patients with Large Subependymal Giant Cell Astrocytoma Associated with Tuberous Sclerosis Complex.

Jiang T, Du J, Raynald, Wang J, Li C.

World Neurosurg. 2017 Nov;107:1053.e1-1053.e6. doi: 10.1016/j.wneu.2017.08.122. Epub 2017 Sep 1.

PMID:
28866062
19.

A circuitry and biochemical basis for tuberous sclerosis symptoms: from epilepsy to neurocognitive deficits.

Feliciano DM, Lin TV, Hartman NW, Bartley CM, Kubera C, Hsieh L, Lafourcade C, O'Keefe RA, Bordey A.

Int J Dev Neurosci. 2013 Nov;31(7):667-78. doi: 10.1016/j.ijdevneu.2013.02.008. Epub 2013 Feb 26. Review.

20.

Subependymal giant cell astrocytoma: current concepts, management, and future directions.

Ouyang T, Zhang N, Benjamin T, Wang L, Jiao J, Zhao Y, Chen J.

Childs Nerv Syst. 2014 Apr;30(4):561-70. doi: 10.1007/s00381-014-2383-x. Epub 2014 Feb 19. Review. Retraction in: Ouyang T, Zhang N, Benjamin T, Wang L, Jiao J, Zhao Y, Chen J. Childs Nerv Syst. 2016 Apr;32(4):761.

PMID:
24549759

Supplemental Content

Support Center